Literature DB >> 7616800

Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy.

U Sigwart1.   

Abstract

Surgery has been the only therapeutic option in patients with hypertrophic obstructive cardiomyopathy who are resistant to drug treatment and sequential pacemaker therapy. I describe a novel catheter-based technique that may replace surgical myocardial reduction in some patients. The technique aims at selective destruction of the hypertrophied part of the left side of the intraventricular septum. If temporary occlusion of the first major septal artery is shown to reduce the intraventricular pressure gradient significantly, absolute alcohol is injected through the inflated balloon catheter to produce a localised infarct. In the first three patients treated with this method, the size of the septal infarct was sufficient to eliminate any subaortic stenosis immediately. Clinical improvement has been maintained up to 12 months. Non-surgical reduction of the septum in hypertrophic obstructive cardiomyopathy warrants further clinical evaluation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7616800     DOI: 10.1016/s0140-6736(95)91267-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  111 in total

1.  Left ventricular opacification during selective intracoronary injection of echocardiographic contrast in patients with hypertrophic cardiomyopathy.

Authors:  P M Elliott; S J Brecker; W J McKenna
Journal:  Heart       Date:  2000-04       Impact factor: 5.994

Review 2.  Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy.

Authors:  H Seggewiss
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

3.  Gated SPECT in patients with hypertrophic obstructive cardiomyopathy undergoing transcoronary ethanol septal ablation.

Authors:  Felix Y j Keng; Su Min Chang; Eduardo Cwajg; Zuo-Xiang He; Nasser M Lakkis; Sherif F Nagueh; William H Spencer; Mario S Verani
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

4.  A TASH experience: post-infarction myocardial oedema necessitating the support of ECMO and occurrence of significant mitral regurgitation.

Authors:  D Basic; H Möllmann; M A Haas; A Rolf; A Jovanovic; Christoph Liebetrau; Sebastian Szardien; J Leick; Oliver Dörr; A Skwara; T Walther; C W Hamm; H M Nef
Journal:  Clin Res Cardiol       Date:  2011-12-27       Impact factor: 5.460

Review 5.  The left ventricular outflow in hypertrophic cardiomyopathy: from structure to function.

Authors:  Magdi H Yacoub; Ismail El-Hamamsy; Karim Said; Gehan Magdi; Fatma Abul Enein; Robert George; Alessandra Rossi; Iacopo Olivotto; Franco Cecchi
Journal:  J Cardiovasc Transl Res       Date:  2009-11-26       Impact factor: 4.132

Review 6.  Hypertrophic cardiomyopathy: from genetics to treatment.

Authors:  Ali J Marian
Journal:  Eur J Clin Invest       Date:  2010-04       Impact factor: 4.686

Review 7.  Transcatheter septal ablation in hypertrophic obstructive cardiomyopathy: a technical guide and review of published results.

Authors:  Angelos G Rigopoulos; Stefanos Sakellaropoulos; Muhammad Ali; Sophie Mavrogeni; Athanassios Manginas; Matthias Pauschinger; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

Review 8.  Alcohol septal ablation for obstructive hypertrophic cardiomyopathy.

Authors:  Charles J Knight
Journal:  Heart       Date:  2006-09       Impact factor: 5.994

9.  Impact of alcohol septal ablation on left anterior descending coronary artery blood flow in hypertrophic obstructive cardiomyopathy.

Authors:  Willem G van Dockum; Paul Knaapen; Mark B M Hofman; Joost P A Kuijer; Folkert J ten Cate; Jurrien M ten Berg; Aernout M Beek; Jos W R Twisk; Albert C van Rossum
Journal:  Int J Cardiovasc Imaging       Date:  2009-02-22       Impact factor: 2.357

10.  Microvascular permeability changes might explain cardiac tamponade after alcohol septal ablation for hypertrophic cardiomyopathy.

Authors:  Jen-Te Hsu; Ju-Feng Hsiao; Jung-Jung Chang; Chang-Min Chung; Shih-Tai Chang; Kuo-Li Pan
Journal:  Tex Heart Inst J       Date:  2014-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.